StreetInsider.com News Articles

Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update

Wed, 07 Oct 2026 14:37:00 -0400

Calgary, Alberta--(Newsfile Corp. - October 7, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that it has received full approval from the National Longevity and Regenerative Therapy Board of The Bahamas (LARTA Board), including ethics approval from the LARTA Ethics Committee, for its commercial Phase 1 study of VesCell™as a treatment for angina, vascular dementia and pain. This milestone advances the Company's clinical development program within The Bahamas' growing longevity and regenerative-medicine sector.

Further to its September 23, 2026 announcement, Hemostemix has submitted a Form 4B to the TSX Venture Exchange seeking price protection

Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update

Wed, 07 Oct 2026 14:37:00 -0400

Further to its September 23, 2026 announcement, Hemostemix has submitted a Form 4B to the TSX Venture Exchange seeking price protection

Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update

Wed, 07 Oct 2026 14:37:00 -0400

Further to its September 23, 2026 announcement, Hemostemix has submitted a Form 4B to the TSX Venture Exchange seeking price protection

Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update

Wed, 07 Oct 2026 14:37:00 -0400

Further to its September 23, 2026 announcement, Hemostemix has submitted a Form 4B to the TSX Venture Exchange seeking price protection

Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update

Wed, 07 Oct 2026 14:37:00 -0400

Further to its September 23, 2026 announcement, Hemostemix has submitted a Form 4B to the TSX Venture Exchange seeking price protection

Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update

Wed, 07 Oct 2026 14:37:00 -0400

Further to its September 23, 2026 announcement, Hemostemix has submitted a Form 4B to the TSX Venture Exchange seeking price protection

Hemostemix to Attend Centurion One Capital's 4th Annual Bahamas Summit

Mon, 28 Sep 2026 14:45:00 -0400

Calgary, Alberta--(Newsfile Corp. - September 28, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that it is presenting at the Centurion One Capital 4th Annual Bahamas Summit at Rosewood Baha Mar in Nassau, The Bahamas, October 19 to October 21, 2026.

The invitation-only summit brings together company executives, institutional investors and family offices for company presentations, panel discussions and one-on-one meetings. Hemostemix intends to discuss VesCell™ commercialization in The Bahamas on the foundation of VesCell's clinical evidence - 498 treatments, seven clinical studies and 11 peer reviewed publications.

The Bahamas clinical program

Hemostemix

Hemostemix to Attend Centurion One Capital's 4th Annual Bahamas Summit

Mon, 28 Sep 2026 14:45:00 -0400

The Bahamas clinical program

Hemostemix

Hemostemix to Attend Centurion One Capital's 4th Annual Bahamas Summit

Mon, 28 Sep 2026 14:45:00 -0400

The Bahamas clinical program

Hemostemix

Hemostemix to Attend Centurion One Capital's 4th Annual Bahamas Summit

Mon, 28 Sep 2026 14:45:00 -0400

The Bahamas clinical program

Hemostemix

Hemostemix files Form 4B for third tranche of private placement

Wed, 23 Sep 2026 16:11:13 -0400

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) is filing a Form 4B to obtain price protection for the closing of the third tranche of a non-brokered private placement, according to a company statement. The offering, first announced June 17, 2026, aims to raise $1,000,000.

Each unit in the offering consists of one common share and one-half of one common share purchase warrant. Each whole warrant allows the holder to acquire one additional common share at CDN$0.12 per share for 24 months from the closing date of the third tranche. If the volume-weighted average trading price of common shares on the TSX Venture

Hemostemix files Form 4B for third tranche of private placement

Wed, 23 Sep 2026 16:11:13 -0400

Hemostemix Non Brokered Private Placement

Wed, 23 Sep 2026 16:10:00 -0400

Calgary, Alberta--(Newsfile Corp. - September 23, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is filing a Form 4B to obtain price protection for the closing of the third tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026, to raise $1,000,000. Each Unit consists of one common share in the capital of the Company (a "Common Share") and one-half of one common share purchase warrant (a "Warrant"). Each whole Warrant entitles the holder to acquire one additional

Hemostemix Non Brokered Private Placement

Wed, 23 Sep 2026 16:10:00 -0400

Hemostemix Non Brokered Private Placement

Wed, 23 Sep 2026 16:10:00 -0400

Hemostemix Non Brokered Private Placement

Wed, 23 Sep 2026 16:10:00 -0400

Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA

Thu, 20 Aug 2026 09:44:00 -0400

Leading cognitive-disorders specialist, Dr. William Shankle, will discuss vascular cognitive impairment, vascular dementia and the proposed clinical trial of VesCell™ (ACP-01) today at 12:00 EST, at https://us06web.zoom.us/webinar/register/WN_nJ8ViLkRSeiU_NXMYJ-jbw

Calgary, Alberta--(Newsfile Corp. - August 20, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce > 130 participants have enrolled to hear Dr. William R. Shankle, MS, MD, FACP, special presentation entitled: "Vascular Cognitive Impairment and Vascular Dementia: Recognizing the Vascular Cause and Exploring the Clinical-Trial Application of VesCell™". The presentation will begin at 12:00 EST and is available through https://us06web.zoom.us/webinar/register/WN_nJ8ViLkRSeiU_NXMYJ-jbw

Dementia debilitates

Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA

Thu, 20 Aug 2026 09:44:00 -0400

Leading cognitive-disorders specialist, Dr. William Shankle, will discuss vascular cognitive impairment, vascular dementia and the proposed clinical trial of VesCell™ (ACP-01) today at 12:00 EST, at https://us06web.zoom.us/webinar/register/WN_nJ8ViLkRSeiU_NXMYJ-jbw
Calgary, Alberta--(Newsfile Corp. - August 20, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce > 130 participants have enrolled to hear Dr. William R. Shankle, MS, MD, FACP, special presentation entitled: "Vascular Cognitive Impairment and Vascular Dementia: Recognizing the Vascular Cause and Exploring the Clinical-Trial Application of VesCell™". The presentation will begin at 12:00 EST and is available through https://us06web.zoom.us/webinar/register/WN_nJ8ViLkRSeiU_NXMYJ-jbw
Dementia debilitates

Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial

Wed, 12 Aug 2026 08:23:00 -0400

Calgary, Alberta--(Newsfile Corp. - August 12, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the appointment of Prof. Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI, as Principal Investigator of Hemostemix' VesCell™ (ACP-01) longevity clinical trial.
The study is designed to investigate whether Hemostemix' VesCell™ can improve measurable dimensions of longevity including cardiovascular health associated with health-span (healthy active aging), improvements in muscle function as measured by the six minute walk test, cognitive function, and immune system improvement as measured by decreased inflammation.
About Prof. Dr. Ernst von Schwarz
Dr. von

Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial

Wed, 12 Aug 2026 08:23:00 -0400

Calgary, Alberta--(Newsfile Corp. - August 12, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the appointment of Prof. Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI, as Principal Investigator of Hemostemix' VesCell™ (ACP-01) longevity clinical trial.
The study is designed to investigate whether Hemostemix' VesCell™ can improve measurable dimensions of longevity including cardiovascular health associated with health-span (healthy active aging), improvements in muscle function as measured by the six minute walk test, cognitive function, and immune system improvement as measured by decreased inflammation.
About Prof. Dr. Ernst von Schwarz
Dr. von

Hemostemix closes second tranche, raises CDN$322,250

Thu, 30 Jul 2026 17:59:11 -0400

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) closed the second tranche of a non-brokered private placement, raising CDN$322,250 through the issuance of 6,445,000 units priced at CDN$0.05 per unit, according to a company statement.

Each unit consists of one common share and one-half of one common share purchase warrant. Each whole warrant allows the holder to acquire one additional common share at CDN$0.12 per share for 24 months from the closing date. The company may accelerate warrant expiry to 30 days' notice if the volume-weighted average trading price on the TSX Venture Exchange reaches or exceeds CDN$0.15 per share for 10 consecutive

Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026

Thu, 30 Jul 2026 17:57:00 -0400

Calgary, Alberta--(Newsfile Corp. - July 30, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the second tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026. The Company raised aggregate gross proceeds of CDN$322,250 under the second tranche through the issuance of 6,445,000 units ("Units") at a price of CDN$0.05 per
Unit.Each Unit consists of one common share in the capital of the Company (a "Common Share") and one-half of one common share purchase warrant (a "Warrant"). Each whole Warrant entitles

Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026

Thu, 30 Jul 2026 17:57:00 -0400

Calgary, Alberta--(Newsfile Corp. - July 30, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the second tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026. The Company raised aggregate gross proceeds of CDN$322,250 under the second tranche through the issuance of 6,445,000 units ("Units") at a price of CDN$0.05 per
Unit.Each Unit consists of one common share in the capital of the Company (a "Common Share") and one-half of one common share purchase warrant (a "Warrant"). Each whole Warrant entitles

Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results

Tue, 28 Jul 2026 12:14:00 -0400

Calgary, Alberta--(Newsfile Corp. - July 28, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous (patient's own stem cells) regenerative medicine company is pleased to announce the VesCell™ Phase I Longevity Clinical Trial protocol has been drafted.
The longevity protocol represents an important milestone in Hemostemix's strategy to expand the clinical application of VesCell™ beyond the treatment of cardiovascular diseases, toward improving healthspan—the number of years people enjoy health, pain free, remaining active, strong, independent, mentally sharp and cognitively competent.
The commercial Phase I clinical trial is designed to study and leverage how VesCell™ improves

Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results

Tue, 28 Jul 2026 12:14:00 -0400

Calgary, Alberta--(Newsfile Corp. - July 28, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous (patient's own stem cells) regenerative medicine company is pleased to announce the VesCell™ Phase I Longevity Clinical Trial protocol has been drafted.
The longevity protocol represents an important milestone in Hemostemix's strategy to expand the clinical application of VesCell™ beyond the treatment of cardiovascular diseases, toward improving healthspan—the number of years people enjoy health, pain free, remaining active, strong, independent, mentally sharp and cognitively competent.
The commercial Phase I clinical trial is designed to study and leverage how VesCell™ improves